The first Integrated m-Health solution for anaphylaxis management.

Project Information

Anapphylaxis

Grant agreement ID: 773344

DOI 10.3030/773344

Closed project

EC signature date 16 May 2017

Start date 1 May 2017

End date 30 September 2017

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

ADAN MEDICAL INNOVATION SL
Spain

Objective

Adan Medical Innovation is a private company focused on the medical devices and the m-health solutions markets. We have patented an m-Health technology for anaphylaxis management, which consists on a smart case for an epinephrine auto-injector linked via Bluetooth to a medical mobile app. Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. The only adequate treatment is an immediate intramuscular epinephrine injection by using an auto-injector. However, patient self-management of auto-injectors has several problems: a) Need to check periodically drug condition, b) low adherence because patients forget carrying the auto-injector, c) difficulties to administer intramuscular epinephrine.
Adanmi has developed the first integrated solution to solve all these issues: a) The smart auto-injector case monitors epinephrine condition; b) The smartphone alerts distance from auto-injector in case the subject forgets it, c) during anaphylaxis it initiates an automated emergency protocol alerting contacts with exact GPS location and providing administration video-instructions.

Fields of science

• engineering and technology › electrical engineering, electronic engineering, information engineering › information engineering › telecommunications › radio technology › bluetooth
• engineering and technology › electrical engineering, electronic engineering, information engineering › information engineering › telecommunications › mobile phones

Programme(s)

• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Topic(s)

• SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme

Call for proposal

H2020-SMEInst-2016-2017

See other projects for this call

Sub call

H2020-SMEINST-1-2016-2017

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ADAN MEDICAL INNOVATION SL

• Net EU contribution: € 50 000,00
• Address: ANGLI 31 4 1 ; 08017 BARCELONA ; Spain
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Este › Cataluña › Barcelona
• Region: Este › Cataluña › Barcelona
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00